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Abstract
Only four drugs are available for the chemotherapy of human African trypanosomiasis or sleeping sickness; Sura-
min, pentamidine, melarsoprol and eflornithine. The history of the development of these drugs is well known and
documented. suramin, pentamidine and melarsoprol were developed in the first half of the last century by the
then recently established methods of medicinal chemistry. Eflornithine, originally developed in the 1970s as an
anti-cancer drug, became a treatment of sleeping sickness largely by accident. This review summarises the devel-
opmental processes which led to these chemotherapies from the discovery of the first bioactive lead compounds
to the identification of the final drugs.
Background
Human African trypanosomiasis or sleeping sickness is a
disease caused by two subspecies of Trypanosoma bru-
cei, T. b. rhodesiense and T. b. gambiense. The parasites
live and multiply extracellularly in blood and tissue
fluids of their human host and are transmitted by
the bite of infected tsetse flies (Glossina spp.). The
occurrence of sleeping sickness is restricted to the distri-
bution of tsetse flies which are exclusively found in sub-
Saharan Africa between 14°N and 20°S [1]. More than
250 discrete active sleeping sickness foci in 36 African
countries are recognised most of which are in rural
areas [2].
Trypanosoma b. rhodesiense is found in East and
southern Africa whereas T. b. gambiense occurs in West
and Central Africa. The course of sleeping sickness is
different depending on the subspecies. Infections with
T. b. rhodesiense lead to an acute form of the disease
while infections with T. b. gambiense give rise to a
chronic infection. The symptoms of the first stage of the
disease, defined by the restriction of trypanosomes to
the blood and lymph system, include fever, headache,
joint pain and itching [3,4]. The clinical signs of the sec-
ond stage of the disease, characterised by the invasion of
trypanosomes into the central nervous system, are neu-
rological and endocrinal disorders [3,4]. If left untreated,
sleeping sickness patients infected with T. b. rhodesiense
will die within months whereas those infected with T. b.
gambiense usually survive for several years.
I nt h el a t e1 9 t hC e n t u r y ,A f r i c ae x p e r i e n c e ds e v e r a l
sleeping sickness epidemics the most devastating of
which was an epidemic with 300,000 to 500,000 deaths
between 1896 and 1906 which mainly affected the
Congo Basin and the Busoga focus in Uganda and
Kenya [5]. The disastrous effect of this epidemic per-
suaded the various colonial administrations to call for
their medical scientists to develop a cure for sleeping
sickness. At that time, the field of chemotherapy was
developing and had begun to make use of the novel
methods of medicinal chemistry, i.e. the identification,
synthesis and development of new chemical entities sui-
table for therapeutic use. In fact, it was for the develop-
ment of early anti-sleeping sickness drugs that medicinal
chemistry was first used [6,7].
Dyestuffs
The synthetic dyestuff industry evolved in the middle of
the 19th Century, primarily in Germany which became
the world leader [8]. The most influential protagonist of
the synthetic dyestuff industry was the German scientist
Paul Ehrlich who was the first to exploit the properties
of dyes for the development of chemotherapies. In 1901,
Ehrlich became interested in the chemotherapy of trypa-
nosomiasis and tested more than 100 synthetic dyes
against Trypanosoma equinum, a species that causes a
disease known as Mal de Caderas in equids, and T. bru-
cei brucei, which is responsible for Nagana, a disease of
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any medium, provided the original work is properly cited.cattle [9]. The only dye displaying trypanocidal activity
was a benzopurpurine compound named Nagana Red
(Fig. 1). When trypanosome-infected mice were treated
with Nagana Red, parasites became undetectable in the
animals for a short period and the treated mice survived
2 days longer than control mice (5/6 days versus 3/4
days). Ehrlich thought that the poor efficacy of Nagana
Red was due to its low solubility which impaired the
absorption of the drug into the bloodstream from the
subcutaneous inoculation site. In 1903, Ludwig Benda
working for Cassella Farbwerke near Frankfurt synthe-
sised a derivative of Nagana Red, called Trypan Red
(Fig. 1), with an extra sulphonic acid function and
enhanced water solubility [10]. Trypan Red proved to be
Nagana Red, R = H 
Trypan Red, R = SO3Na 
Trypan Blue 
Afridol Violet 
Bayer 205, Germanin, Suramin 
Figure 1 Chemical structures of sulphated naphthylamine derivatives with trypanocidal activities.
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in mice [11] but not for infections with other trypano-
some species [12]. Ehrlich investigated another 50 deri-
vatives of Trypan Red and the 7-amino derivative of the
compound was tested by the German physician Robert
Koch during an expedition in 1906 [9]. However, the 7-
amino derivative was not more effective than Trypan
Red itself.
From 1906, the German Bayer pharmaceutical com-
pany supplied the French bacteriologist Maurice Nicolle
and the French zoologist Felix Mesnil from the Pasteur
Institute with benzopurpurine dyes to be tested for try-
panocidal activities [10]. One blue benzopurpurine deri-
v a t i v e ,T r y p a nB l u e( F i g .1 ) ,w a sf o u n dt ob ev e r y
effective in eliminating all trypanosomes from the blood
of infected animals [13,14] but as the drug stained the
skin of the animals bluish it was unacceptable for use in
patients [9,10]. For this reason Wilhelm Roehl a former
a s s i s t a n to fE h r l i c hw h oh a dj o i n e dt h eB a y e rr e s e a r c h
group at Elberfeld in 1905, sought a colourless com-
pounds with trypanocidal activities. The chemists Oskar
Dressel and Richard Kothe of Roehl’s team synthesised
derivatives of Afridol Violet (Fig. 1), a naphthalene urea
compound that was less colour-intensive but also less
trypanocidal in screens carried out by Nicolle and Mes-
nil. Several derivatives, however, displayed better activity
against trypanosomes than the parent compound. In
1917, after the synthesis and screening of more than
1000 naphthalene ureas, the breakthrough came in the
form of Bayer 205 (Fig. 1), later named Germanin, a col-
ourless compound that cured trypanosomiasis in both
experimental animals and in humans [15]. The Bayer
Company understood the political importance of Bayer
205 for the commercial exploitation of African colonies
and offered the formula of the drug to the British Gov-
ernment in exchange for the return of Germany’sl o s t
African territories [16]. When the British declined the
offer, the Bayer Company refused to disclose the chemi-
cal structure of the drug. Eventually, in 1924, the French
pharmacist Ernest Fourneau published the structure of
Bayer 205 [17]. Four years later, the Bayer Company
confirmed that Fourneau’s structure was identical with
that of Germanin. The drug was later renamed suramin
and is still in use in the therapy of early-stage T. b. rho-
desiense sleeping sickness.
Arsenicals
In 1858, the Scottish missionary and explorer David
Livingston had suggested the use of Fowler’s Solution, a
1% aqueous solution of potassium arsenite, for the treat-
ment of sleeping sickness [18], although the causative
agent of the disease was still unknown. In 1902, the
French physician Charles Louis Alphonse Laveran (who
had discovered the malaria parasite in 1880) together
with Mesnil reported that sodium arsenite was effective
in killing trypanosomes in infected laboratory animals.
Although the parasites were quickly destroyed by
sodium arsenite, they reappeared in the blood of the
animals within a few days and caused their death [19].
Two years later, the Canadian doctor Harold Wolferstan
Thomas published a paper describing the successful
therapy of animals experimentally infected with trypano-
somes with the arsenical drug Atoxyl (aminophenyl
arsonic acid; Fig. 2) [20]. The drug had already been
synthesised in 1859 by the French biologist Antoine
Béchamp and was claimed to be 40-50 times less toxic
than arsenic acid [9]; hence the name Atoxyl. The origi-
nal structure of Atoxyl, arsenic acid anilide, assigned by
Béchamp was incorrect and it was Ehrlich and Alfred
Bertheim, Ehrlich’s chief organic chemist, who deter-
mined the correct structure as an amino derivative of
phenyl arsenic acid [6] which was instrumental in the
generation of new analogues (see below). During a trial
to evaluate Atoxyl on sleeping sickness patients in East
Africa, Robert Koch discovered that the compound was
by no means nontoxic: about 2% of treated patients
went blind through atrophy of the optic nerve [9]. Based
on this finding, Koch asked Ehrlich to synthesise deriva-
tives of Atoxyl with reduced toxicity and improved effi-
cacy. Bertheim synthesised a series of N-substituted
Atoxyl derivatives. One such compound, acetylatoxyl or
arsacetin (Fig. 2), was less toxic to mice, but when given
in the high doses needed for therapy, the animals began
to move uncontrollably in circles indicating that the ves-
tibular nerve was damaged [6]. This observation sug-
gested that arsacetin might also cause blindness. In
addition, Ehrlich found that arsacetin was ineffective in
vitro a n dt h e r e f o r ea s s u m e dt h a tt h ec o m p o u n dw a s
metabolised into an active form, probably by a chemical
reduction. To test his hypothesis, he asked Bertheim to
synthesise the two possible types of reduction products
from Atoxyl derivatives: arsenoxides and arsenoben-
zenes. Whereas the arsenoxides were toxic to both try-
panosomes and the host, arsenobenzenes were less
trypanocidal but still more potent than arsenoxides and
less cytotoxic [6,9]. This meant that arsenobenzenes
could be administrated at sufficiently low doses to avoid
the neurotoxicity problems. The most promising arseno-
benzene turned out to be arsenophenylglycine (Fig. 2).
When tested in humans in 1907 it proved to be safe
and effective, except for a few patients who developed a
severe and often fatal hypersensitivity reaction [6,9].
Ehrlich obtained another arsenobenzene, arsenophe-
nol, by inserting a hydroxyl group in para position of
the benzene ring of Atoxyl followed by reduction. This
compound was highly effective against trypanosomes
but prone to oxidation and difficult to purify. Based on
his experience with chemotherapeutic dyes, Ehrlich
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to the hydroxyl group would enhance the chemothera-
peutic activity. The introduction of an amino group led
to the compound 606 or arsphenamine, which was
synthesised by Bertheim in 1907 but which turned out
to be ineffective against trypanosomes [6,9]. Interest-
ingly, however, in 1909 Ehrlich and his colleague Saha-
chiro Hata, a Japanese bacteriologist, discovered that
arsphenamine had excellent curative properties against
syphilis. It became the first truly effective drug for treat-
ment of the disease and was marketed by Farbwerke
Hoechst under the proprietary name Salvarsan, ‘the
arsenic that saves’ [6].
In 1919, the American chemist Walter Jacobs and the
American immunologist Michael Heidelberger reported
the synthesis of tryparsamide (Fig. 2), a derivative of
Atoxyl [21]. As this compound was able to enter the
central nervous system it was the first drug for treating
n i t e c a s r A l y x o t A
As As
N H
O O H
OA Hs
N H
O O H
OH
N H
O O H
n
Arsenophenylglycine 
Tryparsamide 
n e s r a l e M n e s r a l e Mo x i d e  
Figure 2 Chemical structures of main arsenical compounds with trypanocidal activities. With respect to arsenophenylglycine, Ehrlich
thought that it consisted of two molecules joined by a As = As double bond. Years later it was found that arsenophenylglycine and other
arsenobenzenes are polymers of several molecules whose arsenic atoms were linked by single bonds [9].
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nation with suramin. Although tryparsamide also caused
damage to the optical nerve, it remained the drug of
choice for chemotherapy of sleeping sickness until the
early 1960s [21] and was also used in the treatment of
animal trypanosomiasis [22].
In 1938, the Swiss pathologist, microbiologist and che-
mist Ernst Friedheim synthesised melarsen (Fig. 2), a
melamine derivative of Atoxyl [23]. Friedheim intro-
duced the melamine moiety because he observed that all
arsenicals with significant trypanocidal activity contain
nitrogen in one form or another [24]. Although melar-
sen was less toxic than existing drugs, it was more
expensive. Bearing in mind that trivalent arsenicals are
much more potent than pentavalent arsenicals, Fried-
heim synthesised the trivalent analogue of melarsen,
melarsen oxide (Fig. 2). This was very effective against
trypanosomes but also very toxic [25]. Based on the
observation that a diet of Swiss cheese improved the tol-
erability of melarsen oxide in some patients [24], Fried-
heim had the brilliant idea to combine the drug with
dimercaprol, an arsenic antidote also known as British
anti-Lewisite (BAL) developed during World War II to
protect against poisoning by the arsenic gas, lewisite.
The resulting product, melarsoprol (also known as Mel
B) (Fig. 3), was 100 times less cytotoxic but only 2.5
times less trypanocidal than melarsen oxide [26]. Melar-
soprol was introduced in 1949 for the treatment of
sleeping sickness. The major advantage of melarsoprol
over tryparsamide is that it does not show any toxic
effect on the optic nerve. However, melarsoprol causes
reactive encephalopathy in 5-10% of patients, with 1-5%
mortality [3]. Melarsoprol is still the only effective drug
for chemotherapy of second stage of T. b. rhodesiense
sleeping sickness.
Diamidines
In 1929 it was shown for the first time that pathogenic
trypanosomes use enormous amounts of sugar for their
metabolism [27]; within 24 h they consume about twice
their own mass of sugar. In 1935, this knowledge
prompted the American bacteriologist Hildrus Poindex-
ter to treat animals infected with Trypanosoma equiper-
dum, a trypanosome that causes Dourine or covering
disease in horses, with insulin to reduce their blood glu-
cose levels. He discovered that trypanosome-infected
animals subjected to insulin treatment survived longer
and with fewer parasites in the blood compared to con-
trols [28]. In the same year, von Jancsó and von Jancsó
and Schern and Artagaveytia-Allende independently
found that the hypoglycaemic drug synthalin (Fig. 4)
had trypanocidal action in mice and rats [29,30]. In
1937, Yorke and Lourie at the Liverpool School of Tro-
pical Medicine discovered that the anti-trypanosomal
effect of synthalin had nothing to do with lowering the
blood glucose level in the infected animals but that
synthalin itself was trypanocidal [31]. When Harold
King at the National Institute of Medical Research in
London learnt about the trypanocidal action of syntha-
lin, he synthesised and tested related compounds and
found that diamidino-1,11-n-undecane (Fig. 4) was par-
ticularly active against T. b. rhodeseinse in mice [32].
Meanwhile, the English chemist Arthur James Ewins of
the pharmaceutical company May and Baker prepared a
large number of aromatic diamidines in which the polar
amidine groups were separated by two phenyl groups
rather than by a polymethylene group. Many of these
compounds displayed trypanocidal activity, especially
stilbamidine and pentamidine (Fig. 4) [33,34]. Both com-
pounds were also highly effective against human trypa-
nosomiasis [35]. Whereas stilbamidine was later
abandoned, because it caused serious neurological
effects in some patients [36,37], pentamidine is still used
for treatment of the first stage of T. b. gambiense sleep-
ing sickness. Pentamidine is also used in the treatment
of leishmaniasis and Pneumocystis jirovecii pneumonia,
mostly in AIDS patients [38].
In 1977, Das and Boykin reported on the trypanocidal
activity of a series of novel aromatic diamidines, with
DB75 (2,5-bis(4-aminophenyl)-furan; Fig. 4) as the most
trypanocidal compound active against T. b. rhodesiense
in mice and rhesus monkeys [39,40]. As DB75 is poorly
absorbed across the gastrointestinal tract due to its posi-
tively charged amidine group, a prodrug, DB289 (2,5-bis
(4-amidinophenyl)-furan-bis-O-methylamidoxime;
Fig. 4), was synthesised [41]. DB289 was the first oral
drug for treatment of first-stage sleeping sickness to
enter clinical trials [42]. However, an extended phase I
study to complete the safety assessment for registration
of DB289 for sleeping sickness revealed severe liver toxi-
city and delayed renal insufficiency [42]. As a conse-
quence, the program to develop DB289 as an oral drug
for treatment of sleeping sickness was discontinued [42].
Nifurtimox
Nifurtimox, a nitrofuran derivative (Fig. 5), was devel-
oped in the 1960s by the Bayer Company. Its trypanoci-
dal activity was empirically discovered and since 1967 it
has been used for the treatment of Chagas disease
caused by Trypanosoma cruzi in Latin America. The
mode of action of nifurtimox is not clearly known but
may be related to the generation of reactive oxygen spe-
cies which damage cellular components such as DNA,
membrane lipids and proteins [43]. Nifurtimox was also
tried on compassionate grounds for treatment of sleep-
ing sickness patients who were infected with melarso-
prol-resistant T. b. gambiense. Small clinical trials
showed that high dosage of nifurtimox was necessary to
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been evaluated together with eflornithine as combina-
tion therapy for treatment of late-stage T. b. gambiense
sleeping sickness (see below).
DFMO
Eflornithine (a-difluoromethylornithine, DFMO, Fig. 6)
was initially developed in the 1970s [46] as a potential
anti-cancer drug [47]. Eflornithine was one of several
fluorinated analogues of amino acids that were rationally
designed based on a predicted enzyme reaction to gen-
erate mechanism-based inhibitors of amino acid decar-
boxylase. It is a specific and irreversible suicide inhibitor
of ornithine decarboxylase [46,48], the first enzyme
involved in polyamine biosynthesis. Inhibition of
ornithine decarboxylase results in the depletion of the
polyamines putrescine and spermidine, with the conse-
quence of a slowdown in cell proliferation. It also causes
a loss of the unique antioxidant metabolite, trypa-
nothione, which may also play a role in its selective
action and also accounts for the known synergism with
other drugs [49]. The very rapid turnover rate of mam-
malian ornithine decarboxylase (t1/2 = 10-30 min
[48,50]), however, made DFMO ineffective as an anti-
cancer drug.
In 1980, the American biologist Cyrus Bacchi heard
about DFMO and tested the drug in a murine trypano-
somiasis model and showed that DFMO cured mice
infected with a virulent strain of T. b. brucei without
any apparent toxic side effects [51]. Based on this
remarkable result, several clinical trials were carried out
demonstrating that DFMO can cure second-stage T. b.
gambiense sleeping sickness patients who were refrac-
tory to melarsoprol treatment [52-55]. The reason why
DFMO is only active against T. b. gambiense is that the
ornithine decarboxylase of this trypanosome species is
Melarsen oxid BAL 
As
S
S
OH
N
H
N
N
N
N H2
NH2
O H2 +
l o r p o s r a l e M
Figure 3 Reaction of melarsen oxide with British anti-Lewisite (BAL) to produce melarsoprol.
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tolerance of T. b. rhodesiense is due to a faster turnover
rate of the enzyme (t1/2 = 4.3 h) [56]. In 1990, DFMO
was approved for the treatment of human trypanosomia-
sis caused by T. b. gambiense [57] and is currently the
only treatment available for melarsoprol-refractory
sleeping sickness.
In recent years, eflornithine has been tested in combi-
nation with nifurtimox in the treatment of second-stage
T. b. gambiense sleeping sickness [58-60]. A recently
completed multicentre, randomised, phase III trial
revealed that the efficacy of nifurtimox-eflornithine com-
bination therapy is no worse than that of eflornithine
monotherapy [61]. However, this combination therapy
represents a major advance in terms of making the treat-
ment safer, cheaper and easier to administer [61].
Conclusion
The development of the anti-sleeping sickness drugs is
an early example of the employment of medicinal chem-
istry, the stepwise application of structure-activity rela-
tionships in order to increase the trypanocidal activity of
a lead compound and to simultaneously reduce toxic
side effects by modifying its chemical structure. Rational
drug design, the inventive process of finding new drugs
based on the knowledge of a biological target, has so far
produced only one drug for treatment of sleeping sick-
ness, eflornithine, although this drug was initially devel-
oped as an anti-cancer agent. Thus, it seems that the
traditional methods of medical chemistry may be more
effective in the development of new chemotherapies for
this important disease.
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